BFRG News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$9.5M

Volume

261.18K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

BullFrog AI Unveils bfARENAS™ Scenario-based Decision EngineBullFrog AI Holdings, Inc. (NASDAQ: BFRG) announced the launch of bfARENAS™, a scenario-based decision engine designed to help biotech and pharmaceutical companies optimize drug portfolio strategy and clinical trial design. The new tool completes the company's end-to-end AI intelligence workflow by enabling head-to-head comparison of drug programs across multiple strategic scenarios, addressing the industry challenge where approximately 90% of clinical trials fail due to inefficient capital deployment and lack of structured decision-making frameworks.GlobeNewswire Inc. · Mar 25, 2026

ProFound Therapeutics Strengthens Leadership Team with Tom Chittenden as Chief Technology Officer and Laurel Ostrom as Chief Human Resources OfficerProFound Therapeutics appointed Tom Chittenden as Chief Technology Officer and Laurel Ostrom as Chief Human Resources Officer to enhance their AI-driven drug discovery platform and organizational capabilities.GlobeNewswire Inc. · Dec 18, 2025

BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma ClientsBullFrog AI, a technology-enabled drug development company, announced a strategic collaboration with Sygnature Discovery, a UK-based contract research organization. Through this collaboration, Sygnature will introduce BullFrog's AI-driven data insights platform, BullFrog Data Networks™, to its global biopharma client base.GlobeNewswire Inc. · Jun 12, 2025

Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on June 12GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on June 12, 2024, at 4:15 p.m. ET.GlobeNewswire Inc. · May 29, 2024

BullFrog AI Announces Availability of Fireside Chat Recording Featuring CEOs of BullFrog AI and the Lieber InstituteGAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the availability of the recording for the recently held fireside chat. This enlightening session, hosted by RedChip Companies on March 5, 2024, featured BullFrog AI's CEO, Vin Singh, alongside Daniel R. Weinberger M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD).GlobeNewswire Inc. · Mar 8, 2024

BullFrog AI Announces Underwriter’s Decision to Exercise Over-Allotment Option to Purchase 218,382 Shares of the Company’s Common StockGAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced February 21, 2024, the Underwriter’s decision to exercise their over-allotment option to purchase 218,382 shares of the Company’s common stock (the “Option Shares”), pursuant to the Underwriting Agreement, dated January 31, 2024, by and between BullFrog AI Holdings, Inc. and WallachBeth Capital, LLC as representative of the Underwriters (the “Underwriting Agreement”).GlobeNewswire Inc. · Feb 21, 2024

BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChipGAITHERSBURG, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its CEO, Vin Singh, alongside distinguished guest, Daniel R. Weinberger, M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD), will participate in a fireside chat hosted by RedChip Companies on March 5, 2024 at 4:15 p.m. ET.GlobeNewswire Inc. · Feb 9, 2024

BullFrog AI Announces Closing of $5.7 Million Public OfferingGAITHERSBURG, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today the closing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase an additional 226,071 shares of common stock (and/or Pre-Funded Warrants in lieu thereof) and/or warrants to purchase 226,071 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.GlobeNewswire Inc. · Feb 5, 2024

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionShares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results. C.H. Robinson Worldwide posted adjusted earnings of 50 cents per share, missing market estimates if 81 cents per share. The company’s quarterly sales came in at $4.20 billion versus estimates of $4.34 billion. C.H. Robinson Worldwide shares dipped 12.6% to $73.49 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Minim, Inc. (NASDAQ: MINM) shares climbed 57.3% to $6.45. David E. Lazar recently disclosed a 51% active stake in Minim. Clearmind Medicine Inc. (NASDAQ: CMND) jumped 51% to $2.17. Clearmind Medicine announced long-term licensing agreement with BIRAD. NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) climbed 52.9% to $5.00. NeuroBo Pharmaceuticals announced FDA clearance of IND for Phase 1 clinical trial of DA-1726 for the treatment of obesity. FibroBiologics, Inc. (NASDAQ: FBLG) shares climbed 47.4% to $42.90. FibroBiologics announced direct listing on the NASDAQ. Celularity Inc. (NASDAQ: CELU) rose 36% to $0.5191. Celularity said it sees FY24 net sales of $50 million to $56 million. Cimpress plc (NASDAQ: CMPR) jumped 28.8% to $96.90 after the company reported better-than-expected second-quarter financial results and said the board authorized the repurchase of up to $150 million of company shares. TuSimple Holdings Inc. (NASDAQ: TSP) rose 28% to $0.2950. Elevai Labs, Inc. (NASDAQ: ELAB) gained 23.5% to $0.84 after gaining 8% on Wednesday. Asset Entities Inc. (NASDAQ: ASST) climbed 22.8% to $0.5650. Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares jumped 20.4% to $0.6649. Kiora Pharmaceuticals announced a private placement of up to $45 million. Evaxion Biotech A/S (NASDAQ: EVAX) gained 19.5% to $4.70. Evaxion Biotech announced pricing of $15 million public offering of 3.750 million ADS at $4.00 per ADS. Nextracker Inc. (NASDAQ: NXT) rose climbed 18.8% to $53.79 after the company reported better-than-expected third-quarter financial results. SunPower Corporation (NASDAQ: SPWR) jumped 18.1% to $3.5791. BioRestorative Therapies, Inc. (NASDAQ: BRTX) gained 16.4% to $1.8850. Corteva, Inc. (NYSE:Benzinga · Feb 1, 2024

Bullfrog AI Announces Pricing of $5.7 Million Public OfferingGAITHERSBURG, Md., Feb. 01, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today the pricing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase an additional 226,071 shares of common stock (and/or Pre-Funded Warrants in lieu thereof) and/or warrants to purchase 226,071 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.GlobeNewswire Inc. · Feb 1, 2024

BFRGBullfrog AI Holdings, Inc. Common Stock

BFRG

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any BFRG yet.

Related Tickers

Earnings

Mkt Cap

$9.7M

Volume

261.18K

Next Earnings

November 13th